Wall Street analysts predict that Magenta Therapeutics Inc (NASDAQ:MGTA) will announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Magenta Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.42). The business is scheduled to announce its next quarterly earnings report on Thursday, November 8th.

On average, analysts expect that Magenta Therapeutics will report full year earnings of ($3.06) per share for the current year, with EPS estimates ranging from ($3.15) to ($2.96). For the next financial year, analysts expect that the firm will post earnings of ($1.82) per share, with EPS estimates ranging from ($2.35) to ($1.02). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Magenta Therapeutics.

Magenta Therapeutics (NASDAQ:MGTA) last issued its earnings results on Thursday, August 9th. The company reported ($3.13) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($2.03).

Several research analysts recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “overweight” rating and a $18.00 target price on the stock. Cowen began coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “outperform” rating on the stock. Wedbush began coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued an “outperform” rating and a $22.00 price objective on the stock. Goldman Sachs Group began coverage on Magenta Therapeutics in a research report on Monday, July 16th. They issued a “buy” rating and a $18.00 price objective on the stock. Finally, Zacks Investment Research raised Magenta Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $19.33.

A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp purchased a new position in Magenta Therapeutics in the second quarter valued at about $179,000. Casdin Capital LLC purchased a new position in Magenta Therapeutics in the second quarter valued at about $27,484,000. Millennium Management LLC purchased a new position in Magenta Therapeutics in the second quarter valued at about $1,508,000. Nexthera Capital LP purchased a new position in Magenta Therapeutics in the second quarter valued at about $2,025,000. Finally, Platinum Investment Management Ltd. purchased a new position in Magenta Therapeutics in the second quarter valued at about $675,000. 30.31% of the stock is currently owned by institutional investors.

Shares of MGTA traded up $0.31 during trading hours on Tuesday, hitting $9.88. The stock had a trading volume of 28,800 shares, compared to its average volume of 82,668. Magenta Therapeutics has a 12-month low of $8.59 and a 12-month high of $16.33.

Magenta Therapeutics Company Profile

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

See Also: Float

Get a free copy of the Zacks research report on Magenta Therapeutics (MGTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Magenta Therapeutics (NASDAQ:MGTA)

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.